In one of its rare forays into patent law, the U.S. Supreme Court redefined one type of prior art (i.e., the pre-existing disclosures or commercial activities that can invalidate a patent), narrowing the opportunities for inventors who engage in commercial activities prior to filing for a patent. The case is Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., et al., and the patent involved was Helsinn’s U.S. Patent No. 8,598,219, “Liquid Pharmaceutical Formulations of Palonosetron,” issued on Dec. 3, 2013.
Would you like to access the complete CEP Article?
No problem. You just have to complete the following steps.
You have completed 0 of 2 steps.
-
Log in
You must be logged in to view this content. Log in now.
-
AIChE Membership
You must be an AIChE member to view this article. Join now.
Copyright Permissions
Would you like to reuse content from CEP Magazine? It’s easy to request permission to reuse content. Simply click here to connect instantly to licensing services, where you can choose from a list of options regarding how you would like to reuse the desired content and complete the transaction.